Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 126-138 of 138
< Previous 1 ... 4 5 6

  • Mithramycin for Lung, Esophagus, and Other Chest Cancers

    Background: - Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer. Objectives: - To see if mithramycin is safe and effective against different chest cancers. Eligibility: - Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum cancers. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and tumor tissue samples will be used to monitor the cancer before treatment. - Participants will receive mithramycin every day for 7 days, followed by 7 days without treatment. Each 14-day round of treatment is called a cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the drug for as long as the side effects are not severe and the tumor responds to treatment.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Pazopanib Hydrochloride and Abexinostat in Treating Patients with Metastatic Solid Tumors

    This phase I trial studies the side effects and best dose of pazopanib hydrochloride and abexinostat in treating patients with solid tumors that have spread to other parts of the body. Pazopanib hydrochloride and abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma

    This is a first-in-human, open-label, nonrandomized, two-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and / or recommended Phase 2 dose (RP2D) of INBRX-105. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides immune checkpoint blockade of PD-L1 as well as conditional T cell co-stimulation through 4-1BB agonism for localized immune stimulation.
    Location: 2 locations

  • Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

    This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

    This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD and clinical activity of AB928 in combination with AB122 in participants with advanced malignancies.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Trigriluzole with Nivolumab and Pembrolizumab in Treating Patients with Metastatic or Unresectable Solid Malignancies or Lymphoma

    This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or cannot be removed by surgery. Trigriluzole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving trigriluzole in combination with nivolumab and pembrolizumab may work better at treating patients with solid malignancies or lymphoma.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and / or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

    An international, multicenter, single arm Phase II trial to determine the efficacy, safety and quality of life of pazopanib treatment after previous therapy with immune checkpoint treatment. Approximately 100 patients will be enrolled, with approximately 40 of those patients receiving pazopanib as 2nd-line therapy. Patients will receive treatment with standard dose pazopanib until disease progression, unacceptable toxicity, pregnancy, death, discontinuation from the study treatment for any other reason or until study end. All patients will be followed for survival. Patients who discontinue treatment without documented disease progression will be followed for efficacy.
    Location: See Clinical Trials.gov

  • A Study of PSB205 in Subjects With Advanced Solid Tumors

    This is an open-label, multicenter, Phase 1, ascending dose escalation study of PSB205 in subjects with advanced solid tumors. The study will be conducted in 2 parts. Part 1 of the study will be a dose escalation evaluation to determine the maximum tolerated dose (MTD) and to establish a recommended Phase 2 dose (RP2D) of PSB205. This study purpose is to describe the safety and tolerability, to assess Pharmacokinetics (PK) and immunogenicity, and to preliminarily assess the anti-tumor activity of PSB205 in subjects with solid tumors. Part 2 of the study will further evaluate the RP2D in 3 distinct tumor cohorts of approximately 12 subjects each.
    Location: University of Colorado, Denver, Colorado

  • Enzalutamide before Surgery in Treating Patients with Kidney Cancer

    This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Entinostat, Nivolumab, and Ipilimumab in Treating Patients with Metastatic Renal Cell Cancer

    This phase II trial studies the side effect and best dose of entinostat when given together with nivolumab and ipilimumab in treating patients with renal cell cancer that has spread to other places in the body. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving entinostat, nivolumab, and ipilimumab may work better in treating patients with renal cell cancer.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Aldesleukin and Pembrolizumab in Treating Participants with Stage III and IV Melanoma and Renal Cell Cancer

    This phase I / II trial studies the side effects and how well pembrolizumab and aldesleukin work in treating participants with stage III and IV melanoma or renal cell cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Interleukins, such as aldesleukin, are proteins made by white blood cells and other cells in the body and may help regulate immune response. Giving pembrolizumab and aldesleukin may work better in treating melanoma and renal cell cancer.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Atezolizumab, Entinostat, and Bevacizumab in Treating Patients with Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of entinostat when given together with atezolizumab and bevacizumab and how well they work in treating patients with kidney cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab, entinostat, and bevacizumab may work better in treating patients with kidney cancer.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients with Advanced Melanoma, Lung, or Kidney Cancer

    This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer that has spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab and atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving hypofractionated radiation therapy, nelfinavir mesylate, pembrolizumab, nivolumab and atezolizumab may work better in treating patients with melanoma, lung, or kidney cancer.
    Location: See Clinical Trials.gov


< Previous 1 ... 4 5 6